Gilead Sciences | GILD - Ebitda

Stock Price
130.40
Daily Change
-3.24 -2.42%
Monthly
-5.68%
Yearly
26.39%
Q2 Forecast
127.61

Gilead Sciences reported $3.02B in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
ALKERMES USD 100.31M 21.24M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
J&J USD 7.19B 2.32B Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 4.77B 1.11B Dec/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sanofi EUR 3.31B 3.65B Mar/2026
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025